Repare Therapeutics announced the first patient has been dosed in the company’s camonsertib monotherapy non-small cell lung cancer, or NSCLC, expansion of the TRESR clinical trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare announces FDA fast track designation for Lunresertib-Camonsertib combo
- Repare Therapeutics Advances Oncology Trials
- Repare Therapeutics reports Q1 EPS 30c, consensus 2c
- Repare Therapeutics, Debiopharm dose first patient in Module 4 of MYTHIC trial
- Repare Therapeutics Announces Board Changes and FD Disclosure